Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
162 Results for "
antigen presentation
" in MedChemExpress (MCE) Product Catalog:
Products (162)
162 Results for "antigen presentation" in MCE Product Catalog:
Cat. No.: HY-P990119
Target:
Research Areas:
Synonyms: BIIB091
Target:
Research Areas:
Corubrutinib (BIIB091) is an orally active BTK inhibitor with an IC50 of <0.5 nM, Kd of 0.07 nM, and >500-fold kinome selectivity. Corubrutinib suppresses B cell activation, proliferation, differentiation, antibody production, antigen presentation, cytokine secretion, and myeloid cell effector functions. Corubrutinib exhibits favorable pharmacokinetic and preclinical safety profiles, including low genotoxic potential, minimal hepatotoxicity, and no major transporter or CYP inhibition. Corubrutinib can be used for the research of multiple sclerosis .
Cat. No.: HY-175459
PROTAC FAK degrader 3 is a potent and selective FAK PROTAC degrader with a DC50 of 1.08 nM. PROTAC FAK degrader 3 induces the ubiquitination and proteasomal degradation of FAK by binding to CRBN, thereby blocking oncogenic signaling, specifically upregulating MHC-I to enhance antigen presentation, and subsequently activating CD8 + T cell-mediated antitumor immune responses. PROTAC FAK degrader 3 can be used in related research on hepatocellular carcinoma, ovarian cancer, and breast cancer .
Cat. No.: HY-P11280A
Target:
Research Areas:
Cat. No.: HY-155808
CAS No.: 2668267-41-0
STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
Cat. No.: HY-163565
CAS No.: 2770960-52-4
Target:
Research Areas:
BIIB129 is a covalent, selective, orally active, and brain-penetrant BTK inhibitor (Kd = 0.63 nM). BIIB129 binds to Cys481 and forms a hydrogen bond with Asn484, blocking BCR and FcγR signaling. BIIB129 inhibits B cell activation and proliferation, FcγR-induced microglial proliferation, FcγR-mediated ROS production in neutrophils, FcγR-induced TNF secretion in monocytes, and B cell-mediated antigen presentation to T cells. BIIB129 can be used for research on multiple sclerosis .
Cat. No.: HY-P10947
Target:
Research Areas:
Cat. No.: HY-178327
CAS No.: 3039488-61-1
Target:
Research Areas:
DGKα/ζ-IN-2 is a potent, orally active and selective dual DGKα/ζ inhibitor with IC50 values of 23 nM (DGKα) and 1.2 nM (DGKζ). DGKα/ζ-IN-2 exhibits selectivity over other DGK isoforms, such as DGKβ and DGKγ. DGKα/ζ-IN-2 shows robust and dose-dependent immune activation in the presence of antigen presentation in an OT-1 murine model. DGKα/ζ-IN-2 can be used for antitumor immunity .
Cat. No.: HY-183267
Target:
Research Areas:
ERAP1-IN-4 is an orally acvtive endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitor with a pIC50 of 7.9 and an LLE of 5.3. ERAP1-IN-4 inhibits hydrolysis of peptide substrates by ERAP1, with high activity against Allotype1 and Allotype2. ERAP1-IN-4 reduced efficacy against other allotypes, and modulates ERAP1-mediated peptide processing to inhibit antigenic epitope presentation. ERAP1-IN-4 can be used for the research of cancer[1].
Cat. No.: HY-163767
CAS No.: 3003004-76-7
Target:
Research Areas:
Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
Cat. No.: HY-176755
CAS No.: 943316-60-7
Target:
Research Areas:
CCL-34 is a Toll-like receptor 4 (TLR4) activator. CCL-34 significantly induced dendritic cell (DC) CD83 expression and IL-12p70 production in a dose-dependent manner, thereby inducing DC maturation. CCL-34 enhanced the allostimulatory activity of DC on naive CD4+CD45+RA+ T cell proliferation and IFN-γ secretion. CCL-34 further induced antigen presentation ability in mice inoculated with doxorubicin-treated colorectal cancer cells. CCL-34 can be used in studies of immune stimulation.
Cat. No.: HY-P992062
Target:
Research Areas:
Cat. No.: HY-155801
CAS No.: 216014-14-1
Research Areas:
Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage .
Cat. No.: HY-P992389
Cat. No.: HY-P990115
Target:
Research Areas:
Cat. No.: HY-P990716
CAS No.: 2648346-74-9
Synonyms: AZD7789
Target:
Research Areas:
Cat. No.: HY-P992454
Cat. No.: HY-P990185
Target:
Research Areas:
Cat. No.: HY-P991525
CAS No.: 2923542-55-4
Target:
Research Areas:
Cat. No.: HY-P992159
Target:
Research Areas:
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
